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Ukrain is the semisynthetic compound of thiophos-
phate-modified alkaloids from Chelidonium majus L. 
It has cytotoxic and cytostatic effects on cancer cells 
due to ability to be selectively accumulated in tumor 
tissue and activate apoptosis of malignant cells but not 
in healthy cells [1–3]. Also Ukrain possesses an ability 
to increase total count of T-cell and T-helper lym-
phocytes along with decrease of T-suppressor cells 
[4]. Ukrain, like other preparation from C. majus L., 
has modulating effect on macrophage metabolism 
[5, 6]. Comparative assessement of intraperitoneal, 
intramuscular, peroral and intravenous administration 
of Ukrain demonstrated maximal therapeutic efficacy 
of the latest. However, in experimental studies intra-
peritoneal and intravenous introduction are often used 
for systemic administration of preparation [7]. Dosage 
range of Ukrain as an antitumoral and immunomodula-
ting drug is rather wide, since data on its dosage are 
controversial [8, 9]. The aim of our work was to carry 
out comparative investigation of effect of intraperito-
neally administered Ukrain on growth of differ ent forms 
of Ehrlich’s carcinoma.
Experimental animals and experimental tumor 
models. In the experiments, female white inbred mice 
2–3 months old weighting 18–22 g bred in the vivarium 
of Biological Faculty of T.G. Shevchenko Kyiv National 
University (Kyiv, Ukraine) were used. All animal proce-
dures were carried out according to the rules of local 
Ethic Committee.
The strain of Ehrlich’s carcinoma was kindly supplied 
by the National Bank of Cell Cultures and Transplan-
table Experimental Tumors of R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobiology 
(Kyiv, Ukraine). Ehrlich’s carcinoma is a transplantable, 
poorly differentiated malignant tumor which appeared 
originally as a spontaneous murine breast carcinoma. 
It arises in both solid and ascitic forms. To receive the 
solid form, tumor cells (1 х 106) were inoculated subcu-
taneously between the scapulas at the volume of 0.1 ml 
of physiologic solution. To get the ascite form, tumor 
cells (1 х 106) were injected intraperitoneally at the 
volume of 0.3 ml of physiologic solution.
Treatment regimen. Next day after tumor trans-
plantation mice were randomly distributed according 
to their weight and divided into different groups includ-
ing: (i) control set for solid form of Ehrlich’s carcinoma 
(n = 12); (ii) mice bearin g solid form of Ehrlich’s carci-
noma treated with Ukrain (n = 12); (iii) control set for 
ascite form of Ehrlich’s carcinoma (n = 20); (iiii) mice 
bearing ascite form of Ehrlich’s carcinoma treated with 
Ukrain (n = 20). For mice with ascite and solid tumors, 
starting from the 2nd day after tumor cells inoculation, 
Ukrain (Nowicky Pharma, Austria) was administered 
intraperitoneally (25 μg/g, it’s 0.1 LD50) daily for 
a 6 days [7, 10]. The total course dose per animal was 
3000 μg. The animals from control groups received 
intraperitoneal injection of distilled water. Mice were 
under the daily observation, and their weight was 
registered every day. 
Anticancer effect evaluation. The effect of 
Ukrain on growth of solid form of Ehrlich’s carcinoma 
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was evaluated by the indexes of tumor growth inhibi-
tion and average life span of experimental animals. The 
tumor size was recorded (with calliper) for a 31 days. 
Anticancer effect was characterized by growth inhibi-
tion indexes GII, which was calculated using formula: 
GII = ((Vk – Ve) / Vk) x 100%,
where Vk and Ve  — average tumor volumes for experi-
mental and control group correspondingly.
To esti mate effect of Ukrain on tumors growth dy-
namics in the case of ascite form of  Ehrlich’s carcinoma 
the animal weight (monitored every day during the 
study) and the number of Ehrlich’s ascites carcinoma 
cells (EACC), evaluated on the 7-th day after tumor cells 
inoculation and at the moment of experiment cessation 
(15-th day after tumor cells inoculation), were used.
Isolation of EACC from mice peritoneal cavity. 
The EACC were isolated from the peritoneal cavity 
of tumor-bearing mice (control or treated). Two to 
three milliliters of sterile PBS was injected into the 
peritoneal cavity of the mice and the peritoneal fluid 
containing the tumor cells was withdrawn, collected in 
sterile Petri dishes and incubated at 37 °C for 2 h. The 
cells of macrophage lineage adhered to the bottom 
of the Petri dishes. The non-adherent population was 
aspirated out gently and washed repeatedly with PBS. 
The EACC viability was assessed by Trypan Blue dye 
exclusion [11]. 
Cell cycle distribution of cancer cells was deter-
mined by the method of flow cytometry.
The number of phagocyting leucocytes was de-
termined by the method of flow cytometry with use 
of FITC-labelled S.aureus Cowan.
Statist ical  analysis was performed using 
Wilcoxon — Mann — Whitney test. p values < 0.05 
were considered significant.
Ehrlich’s carcinoma is a low immunogenic tumor due 
to the lack of antigenicity and could to grown in all mice 
without alloimmunity provocation. One of the promiss-
ing therapeutic approaches for the treatment of such 
tumor is an elevation of its immunogenicity with the use 
of adjuvant and/or immunomodulating substances. Use 
of Ukrain — cytostatic and immunomodulating prepara-
tion — is one of the example of such therapy. 
In mice with solid form of Ehrlich’s carcinoma, intra-
peritoneal administration of Ukrain simulates systemic 
action of the cytotoxic drug with selective accumula-
tion  in tumor tissue and targeted antineoplastic action. 
At the initial stage of tumor growth statistically signifi-
cant difference in tumor volumes in control and treated 
tumor-bearing mice was absent (Fig. 1). However, some 
tumor growth impairment in treated mice was observed: 
palpable tumors in control tumor-bearing mice ap-
peared on ninth day after tumor cells transplantation, 
while in treated tumor-bearing mice — on fourteenth 
day. Starting from twenty-first day, stable tumor growth 
inhibition (by 29% at average) in mice treated with Ukain 
has been observed. Maximal GII value (54.6) in treated 
animal was registered on the 25-th day after tumor 
cells transplantation. At the moment of the experiment 
cessation the volumes of primary tumors in mice that 
received Ukrain, were about 30% lower compared to the 
control ones (GII = 41.2). 
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Fig. 1. Influence of intraperitoneal administration of Ukrain on 
the growth of solid form of Ehrlich’s carcinoma (n = 12 per group)
Intraperitoneal administration of Ukrain has insig-
nificant positive effect on survival of animals bearing 
solid form of Ehrlich’s carcinoma (Fig. 2). The average 
life span in control tumor-bearing mice was 27.7 ± 
0.7 days, in treated mice — 30.0 ± 0.6. 
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Fig. 2. Influence of intraperitoneal administration of Ukrain on life 
span of mice with solid form of Ehrlich’s carcinoma (n = 12 per group)
Unlike, intraperitoneal administration of Ukrain 
has significant negative effect on survival of animals 
with ascite form of Ehrlich’s carcinoma (Fig. 3). The 
average life span in treated mice was 9.2 ± 0.9 days 
(nearly 1.5-fold lower compared to the control group). 
Enhanced death rate in treated animals has been 
registered from the begining of treatment and till the 
end of experiment.
For mice bearing ascite tumor form intraperitoneal 
administration of Ukrain is local one. Introduction of 
drug at the dose of 25 μg/g to mice with ascite form of 
Ehrlich’s carcinoma has been accompanied by moder-
ate gain in animal weight (upon the average by 15%) 
throughout the treatment course (Fig. 4). 
Table 1. Effect of Ukrain on cell fractions ratio in ascitic fluid of experimental animals bearing ascite form of Ehrlich’s carcinoma
Animal groups
7-th day after tumor cell transplantation 15-th day after tumor cell transplantation
Total EACC 
number (x 106)
Percentage of 
viable EACC 
Persentage of 
adherent cells 
Total EACC 
number (x 106)
Percentage of 
viable EACC 
Persentage of 
adherent cells 
Control tumor-bearing mice (n = 20) 312.0 ± 35.4 92.9 ± 0.8 9.2 ± 3.6 482.1 ± 28.5 90.9 ± 2.5 11.5 ± 4.1
Tumor-bearing mice treated with Ukrain (n = 20) 324.1 ± 42.3 63.2 ± 2.1* 21.1 ± 2.9* 351.0 ± 41.1* 83.5 ± 2.7 19.4 ± 2.7
* In Tables 1–3: difference between control and experiment data is significant, p < 0.05.
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Fig. 3. Influence of intraperitoneal administration of Ukrain 
on life span of mice with ascite form of Ehrlich’s carcinoma 
(n = 20 per group)
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Fig. 4. Influence of intraperitoneal administration of Ukrain on the 
weight of animals bearing ascite form of Ehrlich’s carcinoma 
(n = 20 per group)
Total number of EACC in tumor-bearing mice treated 
with Ukrain at the 7-th day after tumor cells inoculation 
was the same as that in control tumor-bearing mice 
(Table 1). However, the number of viable tumor cells 
was 32% lower than that in control animals. Meanwhile 
the number of adherent cells in ascitic fluid of treated 
animals was near 2 times higher in comparison with 
untreated tumor-bearing mice, that indicates the acute 
inflammation. Probably, just the acute inflammation 
caused accelerating of animals death. Treatment ces-
sation resulted in gradual weight reduction in treated 
animals compared to control tumor-bearing mice.
Later on the weight reduction in treated animals 
became more significant and stable and at the moment 
of experiment cessation was about 40%. At this time 
point the total number of EACC in treated mice was 
27% lower than that in untreated mice, but the num-
ber of viable tumor cells, as the number of adherent 
cells, did not differ significantly from the same indices 
in control tumor-bearing animals.
In addition, we have investigate the number 
of phagocyting leukocytes in peripheral blood of mice 
bearing solid and ascite form of Ehrlich carcinoma 
treated with Ukrain at the moment of experiment ces-
sation. In mice with both solid and ascite form of tumor 
the number of circulating phagocytes was decreased 
as compared with intact animals at a lower degree in 
mice with solid form of Ehrlich’s carcinoma (Table 2). 
It can be considered as a marker of tumor-mediated 
immunosupression.
Table 2. Phagocytic cell number in peripheral blood of mice with different 
forms of Ehrlich’s carcinoma after the therapy with Ukrain 
Animal groups Phagocytic cell number, %
Intact animals 48.01 ± 1.45
Mice with solid form of Ehrlich’s carcinoma,  n = 12  40.01 ± 2.03
Mice with solid form of Ehrlich’s carcinoma treated with 
Ukrain, n = 12 
46.12 ± 2.08
Mice with ascite form of Ehrlich’s carcinoma, n = 20 38.08 ± 2.09
Mice with ascite form of Ehrlich’s carcinoma treated with 
Ukrain, n = 20
54.04 ± 1.11
Treatment with Ukrain was associated with res-
titution of the number of phagocyting leucocytes 
in peripheral blood, more expressed in mice bearing 
ascite tumor variant. It indicates the positive immuno-
modulating action of the drug.
It is known that the antitumoral effect of antineo-
plastic drugs using in targeted anticancer therapy can 
either modulate signaling pathways leading to cell 
cycle regulation or directly alter cell cycle regulatory 
molecules [12]. Ukrain inhibits cancer cell growth by 
induction of G2/M or G0/G1 cell cycle arrest followed 
by apoptosis induction [13, 14]. Analysis of cell cycle 
distribution in ascite, performed at the moment of 
experiment cessation, confirmed of antitumor cell 
cycle targeted effect of Ukrain (Table 3). The number 
of apoptotic cells in ascite of treated mice was about 
30% higher compared to the control ones (even nine 
days later after treatment cessation).
Table 3. Distribution of EACC over cell cycle phases, %
Control tumor-bearing 
mice (n = 20)
Mice treated with Ukrain 
(n = 20)
Apoptotic cells 2.89 ± 0.4 4.72 ± 0.1*
Diploid cells 67.0 ± 2.7 55.7 ± 3.9
G0/G1 diploid cells 40.3 ± 2.9  41.0 ± 2.5  
Diploid cells in
G2/M 28.8 ± 3.9 27.9 ± 4.2
S 31.3 ± 3.3 31.7 ± 4.5
G2/M + S 59.9 ± 3.4 58.7 ± 2.9
Aneuploid cells 29.2 ± 2.1  39.1 ± 3.0*
G0/G1 aneuploid cells 59.8 ± 2.3 60 ± 5.3
Aneuploid cells in
G2/M 8.8 ± 0.9 13.7 ± 1.1*
S 31.3 ± 6.1 30.3 ± 2.2
G2/M + S 42.2 ± 4.8 44.0 ± 3.4
Diploid cell number in ascites of control tumor-bea-
ring animals and mice treated with Ukrain was the same. 
The number of cells in S-phase of cell cycle (characteri-
zing tumor growth rate) was also similar in control and 
treated animals. At the same time significant increase 
in the fraction of G2/M aneuploid cells in mice treated 
with Ukrain has been observed, influencing total number 
of aneuploid cells in treated animals (Fig. 5). 
Thus, treatment with Ukrain resulted in significant in-
hibition of growth of solid form of Ehrlich carcinoma and 
retardation of growth of ascite tumor variant. It is media-
ted by direct apoptotic action of drug on EACC and 
positive immunomodulating effect on tumor-bearing 
organism. However it is necessary to point that in mice 
bearing ascite form of Ehrlich carcinoma intraperitoneal 
administration of Ukrain caused the death rate elevation, 
probably due to the acute local inflammation. 
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Fig. 5. Typical distribution of cells of ascite form of Ehrlich’s 
carcinoma in accordance with cell cycle phases
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